Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
RedHill Biopharma ( (RDHL) ) has issued an announcement.
On February 4, 2025, RedHill Biopharma announced the initiation of a Phase 2 clinical study to evaluate the efficacy of opaganib in combination with Bayer’s darolutamide for treating metastatic castrate-resistant prostate cancer (mCRPC). The study, financially supported by Bayer and the Ramsay Hospital Research Foundation, aims to enhance the effectiveness of standard androgen receptor pathway inhibition treatments by using a companion lipid biomarker test to select patients with poor prognosis. The prostate cancer market, valued at $12 billion, could see significant advancements if this combination proves successful, potentially addressing the challenges of treatment-resistant mCRPC.
More about RedHill Biopharma
RedHill Biopharma Ltd. is a specialty biopharmaceutical company based in Tel Aviv, Israel, focusing on the development of novel therapeutics for oncology, infectious diseases, and inflammatory diseases. The company is involved in multiple U.S. government collaborations for chemical and medical countermeasures and is developing opaganib, a clinical-stage drug for various indications.
YTD Price Performance: -7.67%
Average Trading Volume: 16,098
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.53M
For detailed information about RDHL stock, go to TipRanks’ Stock Analysis page.
